Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Daniela P, Roggeri"'
Autor:
Ferruccio Conte, Daniela Paola Roggeri, Mario Gennaro Cozzolino, Carlotta Rossi, Carlo Zocchetti, Alessandro Roggeri
Publikováno v:
Kidney and Dialysis, Vol 3, Iss 1, Pp 95-110 (2023)
The increase in the number of patients with CKD starting dialysis treatment has become a major health problem in recent years. Osteoporosis is a typical feature of advanced age, which, in the dialysis population, is almost always accompanied by uremi
Externí odkaz:
https://doaj.org/article/10cf6fd85554468d84c934d78d921e51
Autor:
Alessandro Roggeri, Ferruccio Conte, Carlotta Rossi, Mario Cozzolino, Carlo Zocchetti, Daniela Paola Roggeri
Publikováno v:
Drugs in Context, Vol 9, Pp 1-10 (2020)
Background: Patients on dialysis often have secondary hyperparathyroidism (SHPT), a disorder associated with renal osteodystrophy, progressive vascular calcification, cardiovascular disease, and death. The objective of this retrospective observationa
Externí odkaz:
https://doaj.org/article/3fd1d1091eee4ab98eb43f336497b061
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 21, Iss 1 (2020)
Prophylaxis is recognized as the most effective treatment regimen for patients with severe hemophilia A. Prophylaxis with standard half-life (SHL) FVIII products requires frequent intravenous administrations, at least two-three times per week. Freque
Externí odkaz:
https://doaj.org/article/280b437ce64f4c40834341bc1560efa0
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 17, Iss 2, Pp 97-100 (2016)
[Article in Italian]
Externí odkaz:
https://doaj.org/article/495303a02f6248b4940eae9f34761d5c
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 18, Iss 1 (2017)
Externí odkaz:
https://doaj.org/article/a89d726ddd114dc3a12c6f0280f2d3da
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 15, Iss 4, Pp 113-127 (2014)
BACKGROUND: Venous thromboembolism (VTE) is frequently leading to severe complications, particularly deep vein thrombosis (DVT) and pulmonary embolism (PE), and requires high cost healthcare intevention. Rivaroxaban, a novel oral factor Xa inhibitor
Externí odkaz:
https://doaj.org/article/917eae6670804274a28f66d98463e327
Autor:
Daniela P, Roggeri, Alessandro, Roggeri, Elisa, Rossi, Elisa, Cinconze, Marisa, De Rosa, Aldo P, Maggioni, M G, Zogno
Publikováno v:
European Journal of Preventive Cardiology. 21:1090-1096
Acute coronary syndrome (ACS) is the most common cause of morbidity and mortality in Italy and worldwide. Aim of this study was to evaluate the average annual direct healthcare costs for the treatment of patients with a recent hospitalization for ACS
Publikováno v:
Clinical drug investigation. 35(4)
Chronic kidney disease (CKD) is a highly morbid disorder. The most severe form of CKD is end-stage renal disease (ESRD), in which the patient requires some form of renal replacement therapy to survive. The increasing incidence, prevalence, and costs
Autor:
Aldo P, Maggioni, Elisa, Rossi, Elisa, Cinconze, Daniela P, Roggeri, Alessandro, Roggeri, Gianna, Fabbri, Marisa, De Rosa, M C, Dessì
Publikováno v:
Cardiovascular drugs and therapy. 27(4)
To assess the outcomes of patients admitted for ACS and the prescription pattern of antiplatelets of patients discharged alive. From the ARNO Observatory database, we performed a record linkage analysis of hospital discharge and prescription database